$TRDA

Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Other Events. Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 m

Entrada Therapeutics (TRDA) reported positive phase 1/2 trial data for ENTR-601-45 in Duchenne muscular dystrophy patients. The study met safety and tolerability goals, with treated patients showing increased dystrophin and exon skipping. Adverse events were mild. Cohort 2 data is expected in 2027. The company plans higher doses in subsequent cohorts.

MPM BIOVENTURES 2018, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).

MPM BioVentures 2014, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

MPM BIOVENTURES 2018, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).

MPM BioVentures 2014, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

MPM BIOVENTURES 2018, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).

MPM BioVentures 2014, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

MPM BioVentures 2014, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

MPM BIOVENTURES 2018, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).